Domurat M.,Oddzial Chirurgii Onkologicznej |
Sierko E.,Medical University of Bialystok |
Wojtukiewicz M.Z.,Medical University of Bialystok
Nowotwory | Year: 2015
Totally implantable venous access devices (TIVDs) are very convenient, long-term accesses to the central venous vessel. They constitute an indispensable solution for patients with difficulties in accessing peripheral veins requiring chemotherapy, parenteral nutrition, antibiotics and frequent blood samples for testing. Port devices are implanted by physicians of different specialties: surgeons, anaesthesiologists, oncologists and radiologists. Vessel cannulation also can be different: open with venotomy or percutaneous puncture. In order to gain access to the central vein: most commonly used are the right internal jugular and right subclavian veins. Implantation of vascular ports as with any interventional treatment, involves the possibility of acute, early and late complications. Acute complications are directly related to the surgery and are the result of abnormal implantation techniques or anatomical abnormalities. Among the late complications in oncology two are particularly troublesome: catheter-related bloodstream infection and thrombosis. Despite their all limitations and complications associated with the use of vascular ports: for more than three decades was no alternative. Further technological development and education of medical staff allows the use of implantable vascular access systems in many patients, giving great benefit to the therapy and improvement of the quality of life of cancer patients. © Polskie Towarzystwo Onkologiczne.
Koc Z.,Poradnia Specjalistyczna Chirurgii Onkologicznej |
Latka D.,Oddzial Neurochirurgii |
Sachanbinski T.,Oddzial Chirurgii Onkologicznej |
Nasierowska-Guttmejer A.,Zaklad Patologii |
Szawlowski A.W.,Centrum Onkologii Instytut Im. Marii Sklodowskiej Curie
Nowotwory | Year: 2012
Primary lepto-meningeal melanoma represents less than 0.1% of all tumours of the central nervous system. It occurs in two different forms: as a primary malignant lepto-meningeal tumour or as a primary lepto-meningeal melanomatosis. Current review of medical literature showed only 45 such case reports. Due to the lack of characteristic symptoms, each case was discovered by chance during surgery or at the time of autopsy. The histogenesis of primary melanoma of the CNS is still unknown issue. For the time being, many different theories have been proposed but have not become fully proven. In this paper the case of a 66-year old male patient with primary melanoma of lepto-meningeal space cone vertebral core was presented.
Marcinkowska M.,University of Lodz |
Stanczyk M.,Oddzial Chirurgii Onkologicznej |
Klajnert-Maculewicz B.,University of Lodz
Postȩpy higieny i medycyny doświadczalnej (Online) | Year: 2015
Breast cancer is the most frequently occurring cancer in women. It has been confirmed that approximately 30% of patients have overexpression of human epidermal growth factor 2 (HER2) on the surface of tumor cells. Trastuzumab - a recombinant, humanized monoclonal antibody - is directed against this receptor. Its use in traditional chemotherapy (with anthracyclines or taxanes) causes an increase of therapy efficiency. However, the systemic toxicity of the anticancer drugs is still a serious problem. Therefore, new solutions are sought, especially in the field of selective drug transport to tumor cells. Dendrimers are composed of a core and branches. They are the bestknown group of nanoparticles. A lot of publications have shown that they can be used as carriers of various types of molecules, including anticancer drugs. The branched structure provides effective protection against premature release of the drug into the circulatory system. It gives a chance to reduce the dose while maintaining a therapeutic effect, and to reduce the toxicity of the drug for normal cells. Furthermore, the surface of dendrimers can be modified by a monoclonal antibody to achieve a targeted therapy. For that reason synthesis of conjugates of trastuzumab, dendrimers, and anticancer drugs is so crucial. This paper presents an overview of publications about the use of trastuzumab in in vitro, in vivo and clinical studies, as well as the latest developments of biology and chemistry, whose goal is to create the perfect, targeted carrier.
Kolacinska A.,Oddzial Chirurgii Onkologicznej |
Blasinska-Morawiec M.,Oddzial Chorob Rozrostowych |
Dowgier-Witczak I.,Oddzial Chemioterapii |
Kordek R.,Zaklad Patomorfologii |
Morawiec Z.,Oddzial Chirurgii Onkologicznej
Przeglad Menopauzalny | Year: 2012
Background: An axillary pathological complete response (pCR) after neoadjuvant systemic treatment, used in breast cancer with axillary metastases, is defined as no residual cancer in the axilla reported by the pathologist. Aim: The aim of the study is to correlate the ER, PR, HER2 receptor subtype in breast cancer patients axillary node positive with axillary pCR after neoadjuvant systemic treatment. Material and methods: 97 consecutive breast cancer patients with axillary metastases were enrolled in the study. Axillary lymph node dissection was performed after neoadjuvant systemic treatment. Results: Twenty five out of 97 breast cancer patients with axillary metastases achieved an axillary pCR (fraction 0.26). In triple negative ER(-) PR(-) HER2(-), ER(-) PR(-) HER2(+), ER(+) PR(+) HER2(-) and ER(+) PR(+) HER2(+) breast cancer group, these fractions were 0.48 (17/35), 0.21 (3/14), 0.13 (5/39) and 0 (0/9), respectively. Conclusions: The rate of the axillary pCR is statistically significantly higher in triple negative breast cancer patients in comparison with ER(+) PR(+) HER2(-) tumors (p < 0.002; χ2 = 9.639) and ER(+)PR(+)HER2(+) cancers (p < 0.03; χ2 = 5.222). Identification of these patients with the axillary pCR could result in more axilla conserving therapies.
Bebenek M.,Oddzial Chirurgii Onkologicznej |
Blaszczyk J.,Oddzial Chirurgii Onkologicznej
Nowotwory | Year: 2013
Is there an epidemic of prostate cancer in Polish males? Prostate cancer belongs to malignancies that are specific for developed countries. Epidemiological data suggests that, aside from bronchi, lungs, and large intestine, prostate is one of the most frequent locations of male malignancies detected in Europe and United States. In 2008, the fraction of cancers in those aforementioned locations corresponded to 46.2% of all male oncological patients in Poland, and the incidence rate of prostate cancer amounted to 29.9 per 100 000. However, one should note considerable geographical variability of prostate cancer incidence in our country. In 2008 the incidence rate of that malignancy ranged between 20.5 and 43.6 per 100 000, depending on province. Detailed epidemiological analysis of regional data is even more conclusive. During the last 25 years, a systematic reduction could be observed with regards to the number of new cases of bronchus/lung malignancies (the predominant cancer location in that region) diagnosed in men from Lower Silesian province, along with increasing incidence of colorectal and prostate malignancies. This growing tendency in prostate cancer incidence is even more evident when relates the data to Wroclaw, the capital and the largest city of Lower Silesia. Beginning in 2004, prostate malignancies are detected here more frequently than those affecting the large intestine, and in 2009 the number of newly diagnosed prostate cancer cases was similar to that of bronchi and lungs. This data points to an increasing frequency of prostate cancer detection. However, this increasing incidence of prostate cancer seems to be related to progressing ageing of the population and improved diagnostic possibilities rather than to any specific epidemics of this malignancy.